Download MendeleyRepurposed dihydroorotate dehydrogenase inhibitors with efficacy against drug-resistant Acinetobacter baumannii.
Russo, T.A., Umland, T.C., Deng, X., El Mazouni, F., Kokkonda, S., Olson, R., Carlino-MacDonald, U., Beanan, J., Alvarado, C.L., Tomchick, D.R., Hutson, A., Chen, H., Posner, B., Rathod, P.K., Charman, S.A., Phillips, M.A.(2022) Proc Natl Acad Sci U S A 119: e2213116119-e2213116119
- PubMed: 36512492
- DOI: https://doi.org/10.1073/pnas.2213116119
- Primary Citation of Related Structures:
7UT5 - PubMed Abstract:
New antimicrobials are needed for the treatment of extensively drug-resistant Acinetobacter baumannii . The de novo pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) is a validated drug target for malaria and human autoimmune diseases. We provide genetic evidence that A. baumannii DHODH ( Ab DHODH) is essential for bacterial survival in rodent infection models. We chemically validate the target by repurposing a unique library of ~450 triazolopyrimidine/imidazopyrimidine analogs developed for our malaria DHODH program to identify 21 compounds with submicromolar activity on Ab DHODH. The most potent (DSM186, DHODH IC 50 28 nM) had a minimal inhibitory concentration of ≤1 µg/ml against geographically diverse A. baumannii strains, including meropenem-resistant isolates. A structurally related analog (DSM161) with a long in vivo half-life conferred significant protection in the neutropenic mouse thigh infection model. Encouragingly, the development of resistance to these compounds was not identified in vitro or in vivo. Lastly, the X-ray structure of Ab DHODH bound to DSM186 was solved to 1.4 Å resolution. These data support the potential of Ab DHODH as a drug target for the development of antimicrobials for the treatment of A. baumannii and potentially other high-risk bacterial infections.
Organizational Affiliation:
Department of Medicine, Veterans Administration Western New York Healthcare System, Buffalo, NY 14215.
